Compositions and methods for treatment of bone associated diseases
US-2021403514-A1 · Dec 30, 2021 · US
Compositions and methods for treatment of bone associated diseases
US11976099B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11976099-B2 |
| Application number | US-202117393593-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 4, 2021 |
| Priority date | Aug 18, 2016 |
| Publication date | May 7, 2024 |
| Grant date | May 7, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Mutant M-CSF protein, comprising α v β 3 integrin binding motif and pharmaceutical compositions comprising same, are provided. Further, use of the composition for the treatment and or prevention of diseases associated with increased bone resorption are provided.
First claim
Opening claim text (preview).
The invention claimed is: 1. A polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 16, and SEQ ID NO: 19, wherein said polypeptide is characterized by antagonizing c-FMS and/or impairing osteoclast differentiation, and wherein said polypeptide may be further characterized by having diminished non-covalent dimerization. 2. The polypeptide of claim 1 , wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 16 and SEQ ID NO: 19, and wherein residues 25-32 of said SEQ ID NO: 16 or SEQ ID NO: 19 is an RGD motif selected from the group consisting of: SEQ ID NO: 8 (QTRGDSPS), SEQ ID NO: 9 (TYPRGDMCS), and SEQ ID NO: 10 (EPVRGDNIN). 3. An isolated nucleic acid molecule encoding the polypeptide of claim 1 . 4. An expression vector comprising the nucleic acid of claim 3 . 5. A cell transformed or transfected with the expression vector of claim 4 . 6. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutical acceptable carrier. 7. A method for treating a disease characterized by excessive osteoclast differentiation or increased bone resorption in a subject in need thereof, the method comprising the step of administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutical acceptable carrier, thereby treating a disease characterized by excessive osteoclast differentiation or increased bone resorption in a subject in need thereof. 8. The method of claim 7 , wherein said disease associated with increased bone resorption is osteoporosis.
Assignees
Inventors
Classifications
- C07K14/435Primary
from animals; from humans · CPC title
- A61K38/19Primary
Cytokines; Lymphokines; Interferons · CPC title
Drugs for skeletal disorders · CPC title
Cytokines; Lymphokines; Interferons · CPC title
Granulocyte CSF; Granulocyte-macrophage CSF · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11976099B2 cover?
- Mutant M-CSF protein, comprising α v β 3 integrin binding motif and pharmaceutical compositions comprising same, are provided. Further, use of the composition for the treatment and or prevention of diseases associated with increased bone resorption are provided.
- Who is the assignee on this patent?
- Nat Inst Biotechnology Negev Ltd, B G Negev Technologies And Applications Ltd At Ben Gurion Univ
- What technology area does this patent fall under?
- Primary CPC classification C07K14/435. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).